Prelude Therapeutics Inc (PRLD) › Operating Cash FlowPrelude Therapeutics Inc (PRLD) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: -$25.66M2020: -$46.18M2021: -$83.53M2022: -$83.73M2023: -$107.06M2024: -$102.89M2025: -$56.30M-$56.30M2019Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$56.30M+45.3%2024-$102.89M+3.9%2023-$107.06M-27.9%2022-$83.73M-0.2%2021-$83.53M-80.9%2020-$46.18M-79.9%2019-$25.66M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share